Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928186 · ClinicalTrials.gov registry record · NA
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
A NA study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01928186: Completed NA study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by University of Washington.
NCT01928186 is a NA study of Stage IIIA Breast Cancer and HER2/Neu Negative that has completed, run by University of Washington. The registered enrollment target is 28 participants, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928186, a NA study of Stage IIIA Breast Cancer and HER2/Neu Negative, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I-III breast cancer. Comparing results of diagnostic procedures done before and during hormone therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Primary Outcome
Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG Fluorothymidine F-18
- DRUG Run-in (short pre-surgery course) of endocrine-targeted therapy
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-07-20 |
| Phase | NA |
What the finished NCT01928186 record still lists
NCT01928186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 10 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT01928186 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01928186 about?
NCT01928186 is a clinical study titled "FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer". This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I-III breast cancer. Comparing results o...
What is the current status of trial NCT01928186?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2011-09. Estimated completion is 2015-07-20.
What conditions does trial NCT01928186 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, HER2/Neu Negative, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer.
What interventions are being tested in trial NCT01928186?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fluorothymidine F-18 (DRUG), Run-in (short pre-surgery course) of endocrine-targeted therapy (DRUG).
Who is sponsoring clinical trial NCT01928186?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01928186 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01928186's enrollment target sits among peer trials
28 23rd of 29 higher than 7 of 29 other Stage IIIA Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IIIA Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
-
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
COMPLETED · NA
-
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
COMPLETED · NA
-
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
COMPLETED · NA
-
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
COMPLETED · NA
-
Diindolylmethane in Treating Patients With Breast Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia